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The local immunoreactivity of C-reactive protein (CRP) was studied in a heterotopic porcine model of posttranplant
obliterative bronchiolitis (OB). Bronchial allografts and control autografts were examined serially 2–28 days after subcutaneous
transplantation. The autografts stayed patent. In the allografts, proliferation of inflammatory cells (P < .0001) and fibroblasts
(P = .02) resulted in occlusion of the bronchial lumens (P < .01). Influx of CD4+ (P < .001) and CD8+ (P < .0001)
cells demonstrated allograft immune response. CRP positivity simultaneously increased in the bronchial walls (P < .01), in
macrophages, myofibroblasts, and endothelial cells. Local CRP was predictive of features characteristic of OB (R = 0.456–0.879,
P < .05−P < .0001). Early obliterative lesions also showed CRP positivity, but not mature, collagen-rich obliterative plugs
(P < .05). During OB development, CRP is localized in inflammatory cells, myofibroblasts and endothelial cells probably as a
part of the local inflammatory response.
Copyright © 2009 Outi E. Pa¨iva¨niemi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Posttransplant obliterative bronchiolitis (OB) is the major
cause of lung allograft dysfunction and late mortality among
lung allograft recipients [1]. The registry data indicates
that, 5 years after transplantation, 45% of recipients had
developed OB [1]. OB is a manifestation of chronic allograft
rejection with histopathological features that include subep-
ithelial inflammation, epithelial cell injury, and excessive
fibroproliferation, resulting in permanent obliteration of
small airways [2]. Long-term success in lung transplantation
will only be possible when there is better understanding of
the molecular and cellular mechanisms of OB and better
strategies for its treatment.
C-reactive protein (CRP) is an acute-phase protein that
is predominantly synthesized by hepatocytes in response to
inflammation, infection, and tissue damage [3, 4]. Extra-
hepatic synthesis of CRP was first described in human
peripheral blood lymphocytes [5]. Expression in human
neurons [6], carotid arterial endothelial cells [7], normal
vascular tissue [8], coronary artery smooth muscle cells
[9, 10], atherosclerotic plaques [11, 12], and adipocytes [13]
has also been reported. In the human respiratory tract,
epithelial cells in nasal polyps express CRP [14], as do
alveolar macrophages in lung tissue [15].
CRP is used as a clinical marker of acute systemic
inflammation. Pulmonary diseases with inflammatory fea-
tures raise the serum CRP level [16, 17], and there is also
evidence of local pulmonary CRP synthesis [18]. Since OB
has inflammatory features, we hypothesized that local CRP
production could occur in posttransplant OB development.
To investigate this hypothesis, we conducted a detailed CRP
expression analysis in our porcine model of posttransplant
OB [19].
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2. Materials andMethods
2.1. Experimental Model. Bronchial segments were trans-
planted subcutaneously in 11 random-bred unrelated
domestic pigs, each weighing 20 kg. The animals received
humane care in compliance with the “Principles of Lab-
oratory Animal Care” (NIH publication Vol 25, No. 28
revised 1996) and with all specific national legislation.
The protocol was approved by the institution’s Committee
for Animal Research and by the South Finland Provincial
Administration. Special attention was given to anesthesia and
pain relief during surgical procedures.
Animals were anesthetized for surgical procedures as
described previously [20] and euthanized with high-dose
intravenous sodium pentobarbital at the end of the follow-
up. The donor left caudal pulmonary lobe was removed
for preparation of implants. A series of bronchial segments,
1.5 cm in length, were subcutaneously transplanted into the
ventral side of each recipient. In addition to 6 animals with
allograft implants, 5 animals received autograft controls. A
total of 190 samples were harvested through small incisions
on follow-up days 2, 4, 7, 9, 11, 14, 17, 21 and 28. A portion of
each sample (two-thirds) was formalin-fixed and embedded
in paraﬃn, and the rest (one-third) was snap-frozen in liquid
nitrogen and stored at −7◦C until use.
2.2. Histology and Immunocytochemistry. The formalin-fixed
sections (4 μm) were mounted on Vectabond-coated slides
(Vector Labs. Ltd., Peterborough, UK) and processed for
histology (hematoxylin and eosin) and immunocytochem-
istry. Monoclonal mouse antipig antibodies (Sigma Chem-
ical, St.Louis, MO, USA) against vimentin (1 : 1000) α-
smooth muscle cell actin (α-SMA) (1 : 16 000) were used
as described previously [21], along with standard avidin-
biotin-peroxidase techniques [22].
The Frozen sections, 4 μm thick, were cut and air-
dried onto silane-coated slides, fixed in acetone at −20◦C
for 10 minutes and stored at −20◦C until use. The 3-layer
indirect immunoperoxidase method and monoclonal mouse
antibodies detecting swine CD4 and CD8 (VMRD Inc.,
Pullman, Wash, USA) were used in addition to mouse mon-
oclonal antibodies against human monocytes/macrophages
(Oxford Biomarketing, Oxford, UK), also reactive with
porcine macrophages, and against human CRP (Abcam Ltd.,
Cambridge, UK) (1 : 600), also reactive with porcine CRP, as
described previously [23]. As a control, nonspecific mouse
IgG (Dako A/S, Glostrup, Denmark) was used to stain all
sections by an identical protocol.
2.3. Microscopic Assessment. Assessments were performed
on 3 separate bronchi from each sample when available.
Epithelial loss, luminal obliteration, bronchial wall fibrosis
(a pathological increase in connective tissue composed of
fibroblasts and extracellular matrix), and inflammation (the
number of infiltrating inflammatory cells in the tissue) were
graded on a semiquantitative scale. The scale, using scores
ranging from 0 to 3, was as follows: 0 = no alteration,
1 = mild alteration, 2 = moderate alteration (pathological
alterations equal to normal tissue), and 3 = severe alteration
(pathological changes predominant).
CD4+ cells, CD8+ cells, and macrophages were counted
in 3 high-power visual fields for each bronchus that was
assessed. The percentages of CRP-positive cells in the
epithelium and the obliterative plug were counted separately,
and the staining intensity was graded on a scale from 0
to 3, where 0 = negative; 1 = positive cells showing weak
staining; 2 = more intense and/or irregular staining; 3 =
intense, uniform staining. The CRP index was calculated
by multiplying the percentage of CRP-positive cells by the
CRP staining intensity score, a method we previously used to
assess cyclo-oxygenase expression [20]. CRP-positive cells in
the bronchial wall were assessed on a scale from 0–3 based
on the intensity of immunocytochemical staining and the
number of positive cells.
2.4. Statistics. All data are expressed as the mean ± standard
error (SEM). The Mann-Whitney U-test, Z adjusted for ties
(Statistica v.5.1, StatSoft Inc., Tulsa, OKla, USA), was used
for statistical analysis, with P ≤ .05 considered statistically
significant. Spearman’s rank correlation served for correla-
tion analysis.
3. Results
3.1. Histology. On posttransplant day 2, ischemic damage to
the airway epithelium was moderate both in the autograft
controls (grade 1.8 ± 0.3) and in the bronchial allografts
(grad 1.7 ± 0.2). Rapid recovery to normal respiratory
epithelium (94%; P < .0001) occurred in the autografts
within 7 days. In allografts, temporary and partial recovery
on day 4 (grade 0.7±0.2) turned to rapid loss of the epithelial
cells with grade 2.5 ± 0.1 on day 7, when a significant
diﬀerence (P < .001) was apparent compared to autografts;
at this time, most of the preserved epithelium comprised the
pure basal cell layer (88%; P < .0001) in allografts.
Inflammation in the bronchial wall remained low grade
in the autografts (Figure 1). In allografts, the number of
inflammatory cells gradually increased, and there was a
significant diﬀerence compared to autografts from day 4
(P < .0001) on. The onset of fibroproliferation in the
bronchial wall paralleled the increase in inflammation grade,
and fibroproliferation was significantly diﬀerent in allografts
compared to autografts by day 11 (P = .02) (Figure 1).
Obliterative lesions gradually occluded the bronchial lumens
in allografts, showing a significant diﬀerence from autografts
from day 7 (P < .01) on (Figure 1). Severe remodeling of the
bronchial allografts occurred, while autografts stayed patent
with functioning mucus glands.
3.2. Immunocytochemistry. Fibroblasts showed positive
staining for vimentin and α-SMA both in the bronchial wall
and in the obliterative lesions. Intense positivity for α-SMA
was evident in newly formed obliterative plugs, but not in
the mature, collagen-rich, scar-like lesions.
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Figure 1: Bronchial wall alterations in bronchial allografts and
autografts and alterations in the obliterative plug. Variables deter-
mining the histological grade of inflammation and fibrosis of the
bronchial wall are given for bronchial allografts and autograft
controls together with the intensity of immunocytochemistry
against CRP, all on a scale from 0–3. In addition, the number
of macrophages (MP) in the bronchial wall is given for allografts
and autografts. Cells are counted per high power visual field.
The histological grade of luminal obliteration (0–3) is given for
allografts together with the percentage of cells positive for CRP in
the obliterative plug and with the intensity score of the staining.
Autografts remained patent with no observed obliterative plugs.
In the bronchial wall of the control autografts, a few
CD4+ and CD8+ cells were observed throughout follow-
up. An influx of CD4+ and CD8+ cells with CD8+ cell
predominant indicated an immune response in the bronchial
allografts that was significantly diﬀerent from autografts
from day 4 onward (Table 1). The number of macrophages
was highest during the initial ischemic injury and at the
onset of the immune response; macrophages were present in
greater numbers from day 7 (P < .0001) onward in allografts,
showing a statistically significant diﬀerence also on days 9
(P < .0001), 11, 14, 21, and 28 (Figure 1).
During the initial ischemic damage on follow-up day
2, 57% of the respiratory epithelial cells in the autografts
and 48% in the allografts expressed CRP. The CRP staining
intensities were 2.76±0.2 and 2.0±0.2, and the CRP indexes
were 151 ± 22 and 103 ± 20, respectively. CRP expression
rapidly decreased in parallel with epithelial damage in the
allografts: 16% (P < .0001) of preserved cells had a CRP
staining intensity of 0.9 ± 0.5 (P < .01) and a CRP index
of 46±31 (P < .001) on day 7. Moderate to intense epithelial
expression of CRP was observed throughout follow-up in the
recovered respiratory epithelium of autografts.
CRP expression was observed in all implants in the
bronchial wall during initial ischemic damage, and then
decreased in the autografts. In contrast, expression rapidly
increased in the bronchial allografts (Figure 1). A statistical
diﬀerence between autografts and allografts was reached on
follow-up day 9 (P < .01). Expression was not only first
predominantly observed in macrophages (Figure 1), but also
observed in myofibroblasts and endothelial cells (Figure 2).
While the number of macrophages decreased towards the
end of follow-up, the intensity of their staining increased as
did endothelial CRP immunoreactivity. Positive myofibrob-
lasts counted a minority and were observed at the beginning
of follow-up. Correlation analysis showed that the grade of
CRP staining intensity in the bronchial wall on follow-up
days 14, 17, 21, and 28 appeared to be correlated with and
predictive of bronchial wall inflammation, the number of
CD4+ and CD8+ cells, bronchial wall fibroproliferation and
luminal obliteration (Table 2). These are all features that are
characteristic of OB.
In the early obliterative lesions, the majority of cells
including fibroblasts, inflammatory cells, and endothelial
cells showed CRP-positivity with ≥2.0 intensity scores
(Figure 1). After day 11, when 72% of the cells in the
obliterative plug were CRP-positive, the percentage of cells
expressing CRP rapidly decreased. The calculated CRP index
was 175±38 in the early obliterative lesions on day 4, but only
18 ± 4 in the mature, collagen-rich plugs on day 28. There
was a statistically significant diﬀerence in the percentage of
positive cells and in the CRP index on day 9 compared to
day 17 as well on day 14 compared to day 28 (P < .05). The
controls stained negative.
4. Discussion
This study shows that CRP is expressed in the bronchial
wall and in obliterative lesions predominantly not only by
macrophages but also by myofibroblasts and endothelial cells
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Table 1: Immune cell influx in bronchial autografts and allografts. An early influx of CD4+ and CD8+ cells with CD8+ cell predominance
indicates an immune response in the bronchial allografts.
Follow-up day Autografts Allografts
CD4+ cells CD8+ cells CD4+ cells CD8+ cells
2 1.4± 0.2 2.9± 0.4 2.6± 0.5 14.4± 0.5
4 5.5± 3.2 8.6± 1.5 230.7± 4.4 337.7± 3.7
7 9.2± 1.0 12.1± 1.7 330.4± 3.2 361.3± 4.7
9 4.0± 0.6 5.6± 0.6 360.9± 3.9 368.9± 5.0
11 8.1± 0.9 11.2± 1.4 346.2± 3.6 384.4± 5.3
14 8.5± 1.1 11.0± 1.5 357.5± 5.4 372.3± 6.2
17 3.1± 0.7 5.8± 0.9 343.9± 4.5 355.4± 5.2
21 6.3± 0.9 8.0± 0.9 363.7± 5.2 376.4± 5.6
28 6.7± 0.9 8.4± 0.6 357.1± 8.4 363.9± 5.6
1P < .05, 2P < .001, 3P < .0001.
Table 2: Correlations (R) to the grade of bronchial wall CRP. R is given for assessment points with statistical significance (P < .05). The
grade of CRP expression in the bronchial wall turned out to correlate to the inflammatory alterations and bronchial remodeling processes.
Correlations are given from the follow-up day 14 onward. On the follow-up day 14 onward, grade of CRP expression was significantly
(P < .0001) more intense in allografts than in autografts.
Mural inflammation CRP/day 14 CRP/day 17 CRP/day 21 CRP/day 28
day 14 0.658
day 17 0.823 0.900
day 21 0.834 0.522 0.720
day 28 0.879 0.590 0.693 0.716
N of CD4+ cells CRP/day 14 CRP/day 17 CRP/day 21 CRP/day 28
day 14 0.764
day 17 0.663 0.815
day 21 0.480 0.532 0.669
day 28 0.456 0.516 0.595 0.551
N of CD8+ cells CRP/day 14 CRP/day 17 CRP/day 21 CRP/day 28
day 14 0.487
day 17 0.741 0.874
day 21 0.568 0.600 0.672
day 28 0.528 0.475 0.689 0.591
Mural fibrosis CRP/day 14 CRP/day 17 CRP/day 21 CRP/day 28
day 14 0.739
day 17 0.864
day 21 0.525 0.737 0.804
day 28 0.642 0.926 0.841 0.747
Luminal obliteration CRP/day 14 CRP/day 17 CRP/day 21 CRP/day 28
day 14 0.845
day 17 0.795 0.797
day 21 0.813 0.810 0.875
day 28 0.811 0.848 0.868 0.870
in posttransplant OB development. Local CRP expression
was previously observed in respiratory epithelial cells [14, 24]
and in alveolar macrophages [15, 25]. To our knowledge, this
is the first report of CRP expression in pulmonary fibroblasts
and endothelial cells in the lung.
In our porcine model, OB developed invariably in
allografts, while autografts stayed patent, as expected [19,
26]. The histological changes were similar to those seen
in human OB [2, 27] and in rodent models [28, 29].
Neovascularization is rapid in the implants [19]; thus, the
initial ischemic injury totally recurred within one week in
autografts. In addition, partial recovery prior to onset of
the immune response was also observed in the allografts.
The influx of CD4+ and CD8+ cells was indicative of the
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Figure 2: Bronchial wall alterations in bronchial allografts.
Macrophages, fibroblasts (a) and endothelial cells (b) stained
postive for CRP in the bronchial wall. CRP positivity was abundant
in fresh obliterative plugs on the follow-up day 11 (c). Immuno-
cytochemistry against CRP: hematoxylin counterstaining, original
magnification 100x objective (a, b), and 20x objective (c).
cell-mediated immune response [30]. Vimentin and α-SMA
postitivity indicated myofibroblasts in the fibroproliferatory
stage both in the bronchial wall and in the obliterative
lesions [31] and macrophages stained positive with specific
immunocytochemistry.
CRP expression has previously been reported in cortic-
ular tubules and glomerular cells in rejecting kidneys [32].
Measurement of urine CRP in renal transplant recipients is
considered a useful tool in the diagnosis of early allograft
rejection [33]. CRP also has properties to serve as a sensitive
marker of lung injury [25]. However, our study does not
support the use of CRP measurement in the lavation fluid as
an early marker of OB, because local CRP is also expressed in
human lungs in other inflammatory conditions in response
to inflammatory stimuli [24, 34]. Similarly, in our study
autografts constantly produced CRP in the respiratory
epithelium. This probably occurred initially as a response to
the ischemic operative injury and later on as a response to the
constantly increasing pressure inside the bronchial implants
due to intraluminally secreted mucus. We suggest that the
epithelial expression of CRP in autografts is characteristic
of this model. This was also previously observed in induced
nitric oxide synthase and nitrotyrosine expression [35].
Paralleling the immune response in allografts, we
observed CRP expression in the bronchial wall in
macrophages and also in myofibroblasts and endothelial
cells. Alveolar macrophages are known to express CRP
[15]. CRP expression has previously been observed also in
endothelial cells [7] and smooth muscle-like cells [9, 10].
In the present study, the intensity of staining increased
during follow-up in macrophages and endothelial cells, but
was observed only in early myofibroblasts as previously
in smooth muscle-like cells [7] and in early fibrous
plaques [36]. At the end of the follow-up macrophages
stained intensely, as did the endothelium of the numerous
capillaries. The grade of CRP intensity in the bronchial wall
correlated with and was predictive of further inflammation,
the number of CD4+ and CD8+ cells, and fibroproliferation,
including obliteration of the bronchial lumen. All of these
features are characteristic of OB [37]. In autografts, mural
CRP production was turned oﬀ. However, CRP expression
was observed in autografts during the first days of follow-
up, when ischemic damage recurred, and subsequent
inflammation was established. Endothelial CRP production
has been reported in human carotid arteries [7] and in the
aorta [38], but it has not previously been reported in lung
tissue or in cases of lung allograft rejection. In this study,
CRP expression coincided with the remodeling process and
with bronchial wall inflammation as it has previously been
reported to associate with the progression of atherosclerosis
in coronary arteries [36].
Inflammatory cytokines interleukines (ILs) 1 and 6 are
stimulatory, but tumor necoris factor (TNF) is an inhibitory
cytokine for the liver synthesis of CRP [39]. Local CRP
expression is also thought to be a response to inflammatory
cytokines [9] which regulate the immune cascade in lung
allograft rejection. In renal tubular epithelial cells, TNF-
α does not stimulate local CRP expression [32], but in
human pulmonary epithelial cells, CRP is synthesized in
response to cytokines IL6, TNF-α, interferon γ, and IL1β
[24]. Adipocytes are also shown to produce CRP under the
influence of IL6 and TNF-α [13]. Casals et al. suggested that
CRP could modulate lung inflammation by decreasing the
production of TNF-α in alveolar macrophages [25]. We have
previously studied TNF-α in our model of OB [40]. In the
bronchial wall its expression paralleled the immunoreactivity
of CRP. TNF-α expression seems to decline prior to that of
CRP during obliterative airway disease development. This
might be a consequence of stimulating influence of the TNF-
α on CRP expression.
In the early obliterative plug, CRP positivity was
observed in the majority of cells. In the mature plug
expression declined significantly. Thus, as in atherosclerotic
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lesions [38], local CRP in the obliterative plaque contributes
with plaque activity. In maturing carotid artery plaques,
CRP expression is evident in inflammatory cells as well
as in the endothelial cells of newly formed microvessels
[7]. Our study found CRP expression in early obliterative
plugs, but not in the mature, scar-like lesions, in which
the existence of α-SMA was also not expressed. The most
intense CRP expression was observed during the accelerated
inflammatory phase. Thus, it seems that CRP in obliterative
plugs is a local inflammatory response, as in atherosclerotic
lesions [38].
Inhibition of complement activation in OB development
seems to have beneficial eﬀects on graft survival [41]. There
is evidence that CRP limits excessive complement activation
[42] and reduces complement-mediated damage to host
tissue. In addition, CRP and complement components act
in concert to promote clearance of apoptotic cells, which
prevents necrosis [43]. We have demonstrated that apoptotic
cell death is an important mechanism in the process that
leads to graft deterioration in OB after lung transplantation
[44]. The exact role of CRP in our model of OB remains
unresolved. It may be observed that local CRP has a
promoting influence on the inflammatory component [45,
46] and also on allograft rejection.
5. Conclusions
This study documents CRP immunoreactivity in posttrans-
plant OB. There are multiple factors leading to chronic lung
allograft rejection. CRP expression may be a local response to
inflammatory cytokines and may promote the inflammatory
component in OB development.
Abbreviations
OB: Obliterative bronchiolitis
CRP: C-reactive protein
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